Trader consensus on Polymarket reflects an 86.5% implied probability against Anthropic being acquired before 2027, driven by the AI lab's aggressive independence and sky-high valuation. Just yesterday, Anthropic acquired biotech startup Coefficient Bio for $400 million, its second major deal after Bun in late 2025, signaling it's a consolidator bolstering Claude model capabilities in drug discovery and coding rather than a takeover target. A rumored $10 billion funding round in January at a $350 billion valuation—fueled by Amazon, Google, and others—further entrenches its standalone status amid fierce competition with OpenAI and xAI. Absent credible buyout rumors or financial distress, traders see regulatory hurdles and premium pricing as formidable barriers, with no near-term catalysts like bids on the horizon.
基於Polymarket數據的AI實驗性摘要 · 更新於Mergers where Anthropic is subsumed by another entity will count toward a "Yes" resolution.
An announced agreement between Anthropic and an acquiring entity will qualify for a “Yes” resolution, regardless of whether the acquisition is ultimately completed.
The primary resolution source for this market is official information from Anthropic and/or its leadership, however a consensus of credible reporting will also be used.
市場開放時間: Nov 12, 2025, 5:14 PM ET
Resolver
0x65070BE91...Mergers where Anthropic is subsumed by another entity will count toward a "Yes" resolution.
An announced agreement between Anthropic and an acquiring entity will qualify for a “Yes” resolution, regardless of whether the acquisition is ultimately completed.
The primary resolution source for this market is official information from Anthropic and/or its leadership, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...Trader consensus on Polymarket reflects an 86.5% implied probability against Anthropic being acquired before 2027, driven by the AI lab's aggressive independence and sky-high valuation. Just yesterday, Anthropic acquired biotech startup Coefficient Bio for $400 million, its second major deal after Bun in late 2025, signaling it's a consolidator bolstering Claude model capabilities in drug discovery and coding rather than a takeover target. A rumored $10 billion funding round in January at a $350 billion valuation—fueled by Amazon, Google, and others—further entrenches its standalone status amid fierce competition with OpenAI and xAI. Absent credible buyout rumors or financial distress, traders see regulatory hurdles and premium pricing as formidable barriers, with no near-term catalysts like bids on the horizon.
基於Polymarket數據的AI實驗性摘要 · 更新於
警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions